Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.
Harrow Health's (HROW) first-quarter top line is likely to have been driven by its recent product launches.
Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.
Surrozen, Inc. (SRZN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among...
Revvity's (PKI) first-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.
High labor costs and inflationary pressures are likely to have weighed on DaVita's (DVA) first-quarter top line.
Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited Q2 sales.
Lantheus Holdings' (LNTH) first-quarter results are likely to reflect solid top-line results on the back of robust product adoption.
Lamb Weston, NeoGenomics, Surrozen, KE Holdings and Insperity are part of the Zacks Screen of the Week article.
Here we discuss some reasons why investing in Nektar Therapeutics (NKTR) stock now is a good idea despite its several pipeline setbacks.